Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
PLK1
REST API REST API
Homo sapiens
PLK1 is differentially expressed in 261 experiments: 81 organism parts: bone marrow, testis, ... (79 more);, 185 disease states: normal, adenocarcinoma, ... (183 more);, 84 cell types 290 cell lines 34 compound treatments and 75 other conditions.
Synonyms PLK
Orthologs ENSCING00000003627 (Ciona intestinalis)   Plk1 (Mus musculus)   CDC5 (Saccharomyces cerevisiae)   Plk1 (Rattus norvegicus)   plk1 (Danio rerio)   PLK1 (Bos taurus)   PLK1 (Gallus gallus)   polo (Drosophila melanogaster)   plk1 (Xenopus laevis)   PLK1 (Canis familiaris)   (Compare orthologs)
Gene Ontology Term cytosol, spindle midzone, spindle pole, response to antibiotic, M phase of mitotic cell cycle, protein binding, positive regulation of peptidyl-threonine phosphorylation, cytoskeleton, kinetochore, cytoplasm, positive regulation of proteasomal ubiquitin-dependent protein catabolic process, cell proliferation, peptidyl-serine phosphorylation, protein ubiquitination, mitotic cell cycle, anaphase-promoting complex binding, protein tyrosine kinase activity, spindle microtubule, condensed chromosome kinetochore, regulation of mitotic cell cycle, anaphase-promoting complex-dependent proteasomal ubiquitin-dependent protein catabolic process, mitotic prometaphase, ATP binding, midbody, centrosome, regulation of cell cycle, protein kinase binding, nucleus, cytokinesis, G2/M transition of mitotic cell cycle, mitosis, nucleotide binding, protein serine/threonine kinase activity, chromosome, nucleoplasm, G2/M transition DNA damage checkpoint, negative regulation of cyclin-dependent protein kinase activity, protein kinase activity, positive regulation of proteolysis, polo kinase kinase activity, regulation of protein binding, mitotic metaphase/anaphase transition, protein destabilization, polar body extrusion after meiotic divisions, positive regulation of ubiquitin-protein ligase activity, protein phosphorylation, protein localization to chromatin, condensed nuclear chromosome outer kinetochore, positive regulation of ubiquitin-protein ligase activity involved in mitotic cell cycle, regulation of mitotic anaphase, regulation of ubiquitin-protein ligase activity involved in mitotic cell cycle, mitotic prophase
InterPro Term POLO_box_duplicated_dom, Prot_kinase_cat_dom, Ser/Thr_kinase_dom, Tyr_kinase_cat_dom, Ser-Thr/Tyr_kinase, Se/Thr_kinase-like_dom
UniProt Accession Q58A51, P53350, B4E083, D3DWF3
Search EB-eye ENSG00000166851
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-803, E-GEOD-6573, E-MEXP-433, E-GEOD-7540, E-GEOD-3526, ... (26 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-5258, E-GEOD-19639, E-GEOD-18005, E-GEOD-19397, E-GEOD-4717, ... (27 experiments)

Factor Value U/D Experiments
BT474
3
E-MEXP-440, E-MTAB-37, E-MTAB-62
CCRFCEM
2
E-MTAB-37, E-GEOD-24147
MCF-7
2
E-GEOD-20081, E-GEOD-3529
MOLT4
2
E-MTAB-62, E-MTAB-37
H1975
1
E-MTAB-62
H4
1
E-MTAB-37
284 more value(s).


Cell type

studied in E-GEOD-20193, E-GEOD-500, E-GEOD-3920, E-GEOD-4219, E-GEOD-20677, ... (44 experiments)

Factor Value U/D Experiments
721 B lymphoblast
1
2
E-AFMX-5, E-TABM-145
CD4+ T cell
2
3
E-GEOD-16190, E-AFMX-5, E-MTAB-24, E-MTAB-25, E-TABM-145 ... (5 experiments)
CD19+ B cells (neg. sel.)
2
1
E-AFMX-5
cancer cell culture
1
E-GEOD-14990
CD4 positive T-cell
1
E-GEOD-6338
Monocytes
1
E-GEOD-21909
78 more value(s).


Disease state

studied in E-GEOD-3307, E-GEOD-2466, E-TABM-15, E-GEOD-16363, E-MTAB-62, ... (53 experiments)

Factor Value U/D Experiments
glioblastoma
3
E-GEOD-4290, E-MTAB-37, E-GEOD-6014
dermatomyositis
2
E-GEOD-1551, E-MTAB-62
acute lymphoblastic leukemia
2
E-MTAB-62, E-MTAB-37
adrenocortical carcinoma
2
E-TABM-311, E-GEOD-10927
cervical carcinoma
2
E-MTAB-62, E-MEXP-1331
lung carcinoma
2
E-MTAB-37, E-GEOD-6014
179 more value(s).


Compound treatment

studied in E-GEOD-571, E-GEOD-5258, E-GEOD-6907, E-GEOD-1417, E-TABM-782, ... (22 experiments)

Factor Value U/D Experiments
sapphyrin PCI-2054
1
E-GEOD-6400
5-aza-2'-deoxycytidine
2
1
E-MEXP-1269
heregulin
1
E-GEOD-6462
platelet-derived growth factor
1
E-GEOD-1923
control
1
E-GEOD-995
oligomycin
1
E-MEXP-2285
28 more value(s).


Age at diagnosis

studied in E-GEOD-3494

Factor Value U/D Experiments
32
1
1
E-GEOD-3494


Agent
studied in E-GEOD-19519

BioSourceProvider
studied in E-GEOD-19519

Blood/non-blood meta-groups
studied in E-MTAB-62

Bmngrd
studied in E-GEOD-20194, E-GEOD-16716

Cancer site
studied in E-GEOD-4271

cd1a
studied in E-GEOD-22601

Cell treatment
studied in E-MEXP-1192

Cellular component
studied in E-GEOD-1400

Chromosomal aberration
studied in E-TABM-125

Clinical history
studied in E-TABM-234, E-GEOD-19743, E-TABM-125, E-GEOD-21589, E-GEOD-16363 ... (5 experiments)

Clinical info
studied in E-GEOD-19743, E-MTAB-37, E-GEOD-6710, E-GEOD-19348, E-GEOD-4619, ... (8 experiments)

Clinical treatment
studied in E-GEOD-1743, E-GEOD-6532

coriell cell line repository identifier
studied in E-GEOD-19519

development stage
studied in E-GEOD-22601

Developmental stage
studied in E-GEOD-1614, E-GEOD-20033, E-MEXP-2359, E-MTAB-62

Disease staging
studied in E-GEOD-89, E-GEOD-19743, E-GEOD-3325, E-TABM-147, E-GEOD-3013 ... (5 experiments)

Environmental stress
studied in E-GEOD-3720

Estrogen receptor status
studied in E-GEOD-3494, E-GEOD-6532, E-GEOD-20194, E-GEOD-16716

Ethnic group
studied in E-GEOD-20194, E-GEOD-16716

Ethnicity
studied in E-GEOD-16363

family id
studied in E-GEOD-19519

Genetic modification
studied in E-GEOD-4025, E-MEXP-1482, E-GEOD-17385, E-GEOD-20847, E-MTAB-108, ... (6 experiments)

Genotype
studied in E-GEOD-1923, E-GEOD-3494, E-GEOD-2466, E-TABM-43, E-TABM-868, ... (9 experiments)

Gestation age
studied in E-GEOD-14334

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-TABM-263, E-MEXP-1220, E-GEOD-5681, E-GEOD-7011, E-GEOD-12773, ... (12 experiments)

Her2 ihc
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-TABM-234, E-GEOD-21653, E-TABM-276

Individual
studied in E-MTAB-197, E-TABM-325, E-MEXP-1290, E-MEXP-2069, E-GEOD-1926, ... (24 experiments)

Infection
studied in E-MEXP-1274, E-GEOD-12108, E-MEXP-561

Injury
studied in E-GEOD-19743

Irradiate
studied in E-GEOD-1977, E-TABM-321

Karyotype
studied in E-GEOD-7214

Ki67 ihc
studied in E-GEOD-21653

Light
studied in E-GEOD-1725

Material type
studied in E-MEXP-455, E-GEOD-9171

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Metastasis
studied in E-GEOD-18105

Molecular subtype
studied in E-GEOD-21653

Nbefore
studied in E-GEOD-20194, E-GEOD-16716

Observation
studied in E-TABM-276

organ
studied in E-GEOD-24283

Organism
studied in E-GEOD-7540, E-GEOD-1801, E-AFMX-1, E-TABM-84

Organism status
studied in E-GEOD-19188

P53 ihc
studied in E-GEOD-21653

Pcr vs rd
studied in E-GEOD-20194, E-GEOD-16716

Phase
studied in E-GEOD-4888

Phenotype
studied in E-GEOD-19703, E-GEOD-22152, E-GEOD-22309, E-GEOD-21750, E-GEOD-1657, ... (8 experiments)

Population
studied in E-GEOD-4342

Progesterone receptor status
studied in E-GEOD-3494, E-GEOD-6532, E-GEOD-20194, E-GEOD-16716

Protocol type
studied in E-GEOD-3254, E-GEOD-21837, E-GEOD-19445, E-GEOD-19246

Replicate
studied in E-GEOD-10896

RNAi
studied in E-MEXP-2115, E-MEXP-1509, E-GEOD-1676, E-MEXP-1857, E-MEXP-1315, ... (6 experiments)

Sample preparation
studied in E-GEOD-16728

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-19743, E-GEOD-21374, E-MEXP-70, E-GEOD-17400

sbr grade
studied in E-GEOD-21653

Sex
studied in E-GEOD-2466, E-GEOD-16363

Stimulation
studied in E-GEOD-11886, E-GEOD-11428

Strain or line
studied in E-TABM-125

Subtype
studied in E-GEOD-24283

Survival time
studied in E-GEOD-19188

targeted_cell_type
studied in E-MEXP-70

Tbefore
studied in E-GEOD-20194, E-GEOD-16716

Test result
studied in E-TABM-276

Tissue
studied in E-GEOD-30573

Treatment
studied in E-GEOD-16837, E-MEXP-973, E-GEOD-15799, E-GEOD-12198

Treatments comments
studied in E-GEOD-20194, E-GEOD-16716

Tumor grading
studied in E-GEOD-4290, E-GEOD-3494, E-TABM-43, E-GEOD-1561, E-GEOD-4922, ... (6 experiments)

Vehicle
studied in E-GEOD-5258

Processing time: 0.29 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM